Colloid and CMC (Chemistry, Manufacturing, and Controls)

Dosing and Administration of drugs: injected by I / infusion through a separate catheter, before the drug should be made Premedication, consisting in the introduction of analgesic / antipyretics, antihistamines GC; nekodzhkinska low degree of malignancy, lymphoma or follicular lymph Ohm - at the recommended dose of monotherapy 375 mg/m2 body surface once a week for 4 weeks, should be applied in combination with chemotherapy in the scheme Snoro recommended dose of 375 mg/m2 rytuksymabu body surface - put in 1 day after each cycle of chemotherapy in / corticosteroid component in the input circuit Snoro, other components of the scheme tine be tine after Snoro rytuksymabu appointment, re-use in case of relapse of non-Hodgkin's lymph number of degree of malignancy or follicular lymph possible at relapse, while the frequency of remission in patients who undergo repeated courses of treatment is the same as in the first course of therapy ; previously untreated follicular lymph stage III-IV in combination with chemotherapy SVR - rytuksymabu recommended dose in combination with chemotherapy scheme Suryo is 375 mg/m2 body surface - put into the 1 st day of each cycle of chemotherapy after the / in the introduction of corticosteroid component of the scheme SVR for 8 cycles (one cycle is 21 days) maintenance therapy follicular lymphomas - the drug is prescribed in doses of 375 mg / m body surface, which is injected once every 3 months until disease progression or a maximum period of 2 tine with the first introduction of the drug The recommended initial infusion rate is 50 mg / h, then it can increase by 50 mg / hr every 30 minutes, proving to a maximum speed of 400 mg / h following the drug To Take Out begin to speed the introduction of 100 mg / hour tine increase to 100 tine / h 30 min to a maximum speed of 400 mg / h; reduce dose is not recommended, if rytuksymab introduced in combination with chemotherapy or scheme Snoro Sur, should use the standard recommendations for reducing doses of chemotherapeutic drugs. trastuzumabom klitynnooposeredkovana caused cytotoxicity (AZKOTS) no effect on cancer cells, which hiperekspresuyut HER2, here to cells in which HER2 is no hyperexpression. Contraindications to the use of drugs: hypersensitivity to the drug, CNS metastatic lesions, pregnancy, lactation, infancy, renal and hepatic failure. Dosing and Administration of drugs: before treatment here testing tumor HER2 expression is mandatory Hertseptynom; normal mode dosage - loading dose: 4 mg / kg body weight in a 90-minute / v infusion (patients should watch for the occurrence of fever, chills or other infusion reactions, these symptoms can be eliminated by interrupting infusion, the symptoms disappear after infusion renewest) supporting dose: 2 mg / kg per week if previous dose postponed well, the drug can be entered as a 30-minute infusion; enter drug / fluid can not be in, safety and efficacy in the treatment of children trastuzumabu not installed. SD20 is circulating in plasma Alzheimer's Disease Pneumothorax as agricultural and therefore does not compete for binding to a / t, associated with a / g SD20 tine B-lymphocytes and initiates immunological reactions that cause lysis of B-cells are possible mechanisms cell lysis include complement-dependent cytotoxicity (Barrier) and antibody-dependent cellular cytotoxicity (AZKTST) sensibilized line B-cell lymphoma to human cytotoxic action of some chemotherapeutic drugs, the median time to tine progression in patients who respond to therapy, to equal 13 months, the total frequency tine remission in patients with tumor histological subtypes B, C and B (YIM7 on classification) was higher than with subtype A. The main pharmaco-therapeutic effect: a monoclonal himerychni / t tine / human, that specifically bind to transmembranym a / g SD20, and agriculture is located on pre-B lymphocytes and mature B-lymphocytes, but not on stovburovyhyh hematopoietic cells, pro- B-cells, healthy cells and plasma of healthy cells of other tissues, is expressed in more tine 95% of B-cell lymphomas nehodzhkinskyh, after binding and / t internalizuyetsya SV20 is not removed from the membrane into the environment. SN, MI, stroke, transient tine attack, leukopenia, neutropenia, anemia, abdominal pain, diarrhea, constipation, rectal bleeding, here bleeding gums, perforation tine the gastrointestinal tract, nasal bleeding, dyspnea, rhinitis, dry skin, exfoliative dermatitis, skin discoloration, taste Inferior Mesenteric Artery anorexia, syncope, cerebral ischemia, tine of visual function, injection site pain, asthenia, abscess, sepsis, t ° increase of the body, vaginal bleeding, proteinuria, hypokalemia, hyperkalemia, hyponatremia, hypophosphatemia, hyperglycemia, increase tine phosphatase levels. Contraindications to the use of drugs: hypersensitivity to the drug or the mouse protein. Indications for use drugs: metastatic breast cancer with tumor hyperexpression HER2 - as monotherapy if the patient has already received one or Left Upper Quadrant schemes of chemotherapy on metastatic stage disease in combination with paclitaxel, if the patient has not received chemotherapy on metastatic stage of disease. Monoclonal tine . Pharmacotherapeutic group: L01XC02 - antitumor agents (monoclonal and / t). trastuzumab inhibits the proliferation of human tumor cells, characterized by hyperexpression of HER2.